January 2018
We’ve updated our policy on continuous glucose monitoring systems
The safety and effectiveness of U.S. Food and Drug Administration-approved continuous glucose monitoring systems has been established. Both the intermittent (72 hours or greater) and continuous basis systems may be considered useful therapeutic devices for patients meeting the relevant patient selection criteria.
Two additional procedure codes – K0553 and K0554 – are now covered when medically necessary. This policy was effective July 1, 2017.
|